Finance

Lists
Why is GANX up 2,14%?
Dive Deeper
GANX:NASDAQ
Gain Therapeutics Inc
1,20 US$
+2,14%
(+0,025) 1D
1,19 US$
-0,42% (-0,0050)
After hours
Closed: 28 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GANX...
Open
1,16 US$
High
1,20 US$
Low
1,16 US$
Mkt. cap
52,15 მლნ.
Avg. vol.
599,68 ათ.
Volume
400,42 ათ.
52-wk high
4,34 US$
52-wk low
1,14 US$
EPS
-0,51 US$
Beta
0,19
Shares outstanding
43,64 მლნ.
No. of employees
21
Open
1,16 US$
High
1,20 US$
Low
1,16 US$
Mkt. cap
52,15 მლნ.
Avg. vol.
599,68 ათ.
Volume
400,42 ათ.
52-wk high
4,34 US$
52-wk low
1,14 US$
EPS
-0,51 US$
Beta
0,19
Shares outstanding
43,64 მლნ.
No. of employees
21
News stories
From web sources and news partners
Investing.com
Investing.com
·
5 საათის წინ
Gain Therapeutics appoints Jeanette Weidner as vice president, finance
TradingView
TradingView
·
6 საათის წინ
Gain Therapeutics appoints Jeanette Weidner as VP of Finance
About Gain Therapeutics Inc
CEO-
Employees21
Founded2017
Headquarters-
Sector-
Websitegaintherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to GANX in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for GANX in the last 3 months.
Highest
Current 1,20 US$
8,00 US$ (+569,46%)
Average
7,20 US$ (+502,51%)
Lowest
5,00 US$ (+318,41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Shrader
BTIG
Buy
Maintained
5,00 US$
+318,4%
10/05/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
8,00 US$
+569,5%
10/05/2026
Jason McCarthy
Maxim Group
Buy
Maintained
7,00 US$
+485,8%
10/01/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Maintained
8,00 US$
+569,5%
08/18/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
8,00 US$
+569,5%
08/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
2,81 მლნ.
2,32 მლნ.
2,74 მლნ.
2,12 მლნ.
Cost of revenue
2,81 მლნ.
2,32 მლნ.
2,74 მლნ.
2,12 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,98 მლნ.
2,15 მლნ.
2,61 მლნ.
2,56 მლნ.
Operating expense
1,98 მლნ.
2,15 მლნ.
2,61 მლნ.
2,56 მლნ.
Total operating expenses
4,79 მლნ.
4,47 მლნ.
5,35 მლნ.
4,68 მლნ.
Operating income
-4,79 მლნ.
-4,47 მლნ.
-5,35 მლნ.
-4,68 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
-4,74 მლნ.
-4,47 მლნ.
-5,43 მლნ.
-4,57 მლნ.
EBT excluding unusual items
-4,74 მლნ.
-4,47 მლნ.
-5,43 მლნ.
-4,57 მლნ.
Income tax expense
549,29 ათ.
70,12 ათ.
183,07 ათ.
104,07 ათ.
Effective tax rate
-11,60%
-1,57%
-3,37%
-2,28%
Other operating expenses
-
-
-
-
Net income
-5,28 მლნ.
-4,54 მლნ.
-5,61 მლნ.
-4,68 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,15
-0,11
-0,13
-0,11
Interest and investment income
83,30 ათ.
88,58 ათ.
93,34 ათ.
60,73 ათ.
Interest expense
-
-
-
-
Net interest expenses
83,30 ათ.
88,58 ათ.
93,34 ათ.
60,73 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-4,78 მლნ.
-4,46 მლნ.
-5,34 მლნ.
-4,67 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები